Issue link: https://www.e-digitaleditions.com/i/1515319
This section provides information that may be useful in research and development or manufacturing. Content is provided by the companies listed. No endorsement or preference is intended. 30 February 2024 Inhalation SPECIAL SECTION Formulation Development/Excipients This section of Inhalation provides information that may be useful in research and development or manufacturing. Content is provided by the companies listed. No endorsement or preference is intended. Development through commercial manufacturing With 30+ years of inhalation experience, Catalent helps companies navigate complex product devel- opment challenges to ensure a timely development timeline. Our US facilities in Raleigh, North Car- olina and Boston, Massachusetts offer end-to-end expertise, pilot- through commercial-scale equipment (including one of the world's largest pharmaceutical spray dryers) for lactose blends and spray-dried dry powder inhalers (DPIs), the latest in drum-based cap- sule filling (drum lab through Modu-C), and facilities capable of potent handling as well as low-humidity conditions to meet all your development through commercial needs. Catalent US: + 1 888 SOLUTION (765-8846) www.catalent.com Inhaled drug delivery services Vectura provides innovative inhaled drug delivery services, with 25 years of experience helping custom- ers succeed in bringing inhaled medicines to market. Combining formulation development expertise and differentiated proprietary technology from pre-clinical to commercial phases, Vectura has expertise in deliver- ing a broad range of complex inhaled therapies across a variety of platforms, including dry powder inhalers (DPIs), pressurized metered dose inhalers (pMDIs) and nebulizer products for small molecules, biologics, complex combinations and generic products. Vectura UK: +44 1249 667700 info@vectura.com www.vectura.com Developing and manufacturing of inhalation devices Recipharm offers a fully integrated, drug/device com- bination product service for developing and manu- facturing inhalation drug products and devices to the global pharmaceutical market, including pressurized metered dose inhalers (pMDIs), soft mist inhalers (SMI), dry powder inhalers (DPIs), unit-dose and multi-dose nasal sprays. By developing inhalation products with the device and commercial manufac- ture in mind, we can eliminate hurdles and reduce time to market. Trust Recipharm to take your prod- uct from concept to commercialization and deliver expertise at every stage. Recipharm UK: +44 1553 691000 www.recipharm.com